Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Imugene wins FDA support, funding risk remains

Imugene (ASX: IMU) received a major regulatory boost this week after the US Food and Drug Administration confirmed support to advance its cancer therapy Azer-Cel into a pivotal Phase 3 study. Written minutes from a November 21 Type C meeting showed clear alignment on trial design, patient population, endpoints, and the accelerated approval pathway for treating diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. For a stock that has fallen roughly 76% over the past 12 months, the key question is whether this FDA backing changes the investment case or if balance sheet concerns make this too risky to touch.

What are the Best ASX Biotech stocks to invest in right now?

Check our buy/sell tips

Why the FDA Endorsement Matters for Azer-cel

The FDA’s written confirmation removes much of the regulatory guesswork that typically weighs on early-stage biotechs. The agency agreed that patients with advanced DLBCL (a type of blood cancer), even those whose disease came back after CAR T therapy, can be included in the trial. This is significant because these patients have very few treatment options left, making Azer-Cel a potential lifeline.

The clinical results supporting this pathway are strong. Updated data from the ongoing Phase 1b trial show an 82% overall response rate in CAR T-relapsed DLBCL patients and an 83% response rate in CAR T-naive patients. To put that in perspective, response rates above 70% are considered impressive for patients who have already failed multiple treatments. These numbers suggest Azer-Cel could compete effectively with existing therapies.

What makes Azer-Cel stand out is that it is an “off-the-shelf” therapy. That may sound technical, but the benefit is straightforward. Traditional CAR T treatments require doctors to extract cells from each patient, send them away for modification, and wait weeks for them to come back. With Azer-Cel, the treatment is already made and ready to use immediately. For cancer patients running out of time, this could be a game-changer.

The Bull Case Meets the Balance Sheet Reality

The positives here are genuine. Imugene holds FDA Fast Track designation, which speeds up the review process. The response rates are impressive. An oral presentation at the ASH 2025 medical conference should attract more attention from oncologists and potential partners.

However, the financial picture is concerning. Imugene has approximately AUD 34 million in cash but burns through roughly AUD 92 million per year. Simple math indicates that the company has less than six months of runway at its current spending levels. Phase 3 trials are expensive, often costing tens of millions of dollars, so a capital raising appears almost certain. This means existing shareholders will likely face dilution.

The market cap of around AUD 70-80 million might seem cheap for a company approaching pivotal trials. But investors must weigh this against the near-certain need for fresh funding and the binary nature of clinical outcomes, where success could mean substantial gains but failure could be devastating.

The Investor’s Takeaway

In our view, Imugene is a high-risk, high-reward biotech play that does not suit conservative portfolios. The FDA endorsement genuinely reduces regulatory risk, but it does not solve the funding challenge hanging over the company.

For speculative investors comfortable with binary outcomes and potential dilution, the low share price might be attractive if the Phase 3 trial goes well. Still, most investors should probably wait until the company explains how it plans to raise money before investing heavily.

Key things to watch:

• When the Phase 3 trial officially begins
• Any announcements about raising capital
• How the company’s work is received at ASH 2025